Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Force Oncology AB
AB
Active
Org 5593005696
Stockholm
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2021
1-4 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
SEK 0
EBITDA margin
—
+18% vs 2023
Equity ratio
65.6%
Financial strength
Net profit 2024
SEK -46K
+13% vs 2023
EBITDA — year on year
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2021
0M
0%
2022
0M
0%
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
SEK 0
—
EBITDA
SEK -14K
+18%
Net profit
SEK -46K
+13%
Total assets
SEK 625K
+93%
Equity
SEK 410K
+1477%
Employees
—
—
Company information
Legal name
Force Oncology AB
Org number
5593005696
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
8 februari 2021
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva utveckling och försäljning inom medicintekniska produkter och därmed förenlig verksamhet.
Contact
Address
Stockholm
Email
fredrik.juto@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Stockholm
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
0M
2024
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
0M
2024
Income statement
SEK thousands
Item
2021
2022
2023
2024
Revenue
0
0
0
0
Staff expenses
—
—
—
—
EBITDA
−5
−10
−17
−14
Depreciation & amort.
−0
−0
−0
−0
EBIT
−5
−10
−17
−14
Net financials
—
−12
−35
−32
Profit before tax
−5
−22
−53
−46
Tax
−0
−0
−0
−0
Net profit
−5
−22
−53
−46
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
Total assets
23
316
324
625
Equity
20
14
26
410
Long-term debt
0
275
200
125
Short-term debt
2
28
98
90
Total debt
2
303
298
215
Financial ratios
5-year trend
EBITDA margin
-1400000.0%
This company
15.8%
Market median
-8860859% vs market
2021
2024
Equity ratio
65.6%
This company
38.2%
Market median
+72% vs market
2021
2024
Return on equity
-11.2%
This company
18.4%
Market median
-161% vs market
2021
2024
Net profit margin
-4600000.0%
This company
8.1%
Market median
-56790223% vs market
2021
2024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2021
2024
Debt / equity
0.52×
This company
0.62×
Market median
+16% vs market
2021
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-02-01 – 2021-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (1)
FR
Fredrik Robert Juto
Chief Executive Officer
Chief Executive Officer
2022
Board of directors
Non-executive oversight
Name
Role
Member since
Current (1)
IK
Ingrid Kristina Maria Lind Juto
Deputy Board Member
2022
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Eldhunden AB
Company
100%
100%
2023
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Eldhunden AB
Force Oncology AB
(this company)
Board network connections
Board members of Force Oncology AB also hold positions in
0
other companies.
Person
Role here
Other companies
Fredrik Robert Juto
Chief Executive Officer
0 companies
Ingrid Kristina Maria Lind Juto
Deputy Board Member
0 companies